glp 1 or tirzepatide Dose-equivalence reference based on pivotal GLP-1/dual-agonist trials: SURMOUNT-1 (tirzepatide/Zepbound, 72 weeks) STEP-1 (subcutaneous semaglutide/Wegovy, 68 weeks) OASIS-4 (oral semaglutide/Wegovy, 64 weeks). For educational comparison only—these are Tirzepatide (GLP-1 / GIP)

Disclosure timing: Medication type and pharmacy routing are resolved after clinician review

Higher-dose formulations approved for weight management produce more substantial losses: semaglutide 2.4 mg (Wegovy) typically achieves 15-17% of baseline body weight loss, while liraglutide 3.0 mg (Saxenda) averages 5-7%

I dose both blends subcutaneously, in the abdomen or thigh, once daily for the first three to four weeks after surgery

Per quanto tempo

It has been demonstrated that VC contributes to an increased risk for CV morbidity and all-cause mortality and was identified both as an independent predictor of poor clinical outcomes and an interventional target for the CKD population (Rennenberg et al., 2009

Body Lift For patients who have lost a massive amount of weight (often 75+ pounds), a lower body lift may be necessary